NASDAQ:DERM - Dermira Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dermira Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.74 0.00 (0.00 %) (As of 02/16/2020 01:28 PM ET) Add Today's Range$18.73Now: $18.74▼$18.7650-Day Range$14.51MA: $17.89▼$19.1952-Week Range$5.25Now: $18.74▼$19.48Volume637,154 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:DERM Previous Symbol CUSIPN/A CIK1557883 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees333 Outstanding SharesN/AMarket CapN/A Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive DERM News and Ratings via Email Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DERM Rates by TradingView Dermira (NASDAQ:DERM) Frequently Asked Questions What is Dermira's stock symbol? Dermira trades on the NASDAQ under the ticker symbol "DERM." How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.40) by $0.34. The biopharmaceutical company earned $11.53 million during the quarter, compared to analysts' expectations of $11.07 million. View Dermira's Earnings History. When is Dermira's next earnings date? Dermira is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dermira. What price target have analysts set for DERM? 9 equities research analysts have issued 12 month price targets for Dermira's shares. Their forecasts range from $14.00 to $25.00. On average, they anticipate Dermira's stock price to reach $18.96 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price. View Analyst Price Targets for Dermira. What is the consensus analysts' recommendation for Dermira? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira. What are Wall Street analysts saying about Dermira stock? Here are some recent quotes from research analysts about Dermira stock: 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/14/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019) 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019) Has Dermira been receiving favorable news coverage? Media headlines about DERM stock have been trending neutral recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dermira earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Dermira. Are investors shorting Dermira? Dermira saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 5,610,000 shares, a decline of 17.5% from the January 15th total of 6,800,000 shares. Based on an average trading volume of 2,400,000 shares, the short-interest ratio is currently 2.3 days. Approximately 12.4% of the company's stock are sold short. View Dermira's Current Options Chain. What other stocks do shareholders of Dermira own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Exelixis (EXEL), AT&T (T), Novavax (NVAX), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD) and AbbVie (ABBV). Who are Dermira's key executives? Dermira's management team includes the folowing people: Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43) Who are Dermira's major shareholders? Dermira's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (5.60%), Oracle Investment Management Inc. (4.64%), Bank of America Corp DE (3.70%), State Street Corp (1.80%), Broadfin Capital LLC (1.64%) and Earnest Partners LLC (1.48%). Company insiders that own Dermira stock include David E Cohen, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira. Which institutional investors are selling Dermira stock? DERM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Credit Suisse AG, Citigroup Inc., Fred Alger Management LLC, Renaissance Technologies LLC, Sofinnova Investments Inc., Panagora Asset Management Inc. and Partner Investment Management L.P.. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira. Which institutional investors are buying Dermira stock? DERM stock was acquired by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Jacobs Levy Equity Management Inc., Broadfin Capital LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Earnest Partners LLC, EAM Global Investors LLC and EAM Investors LLC. View Insider Buying and Selling for Dermira. How do I buy shares of Dermira? Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Dermira's stock price today? One share of DERM stock can currently be purchased for approximately $18.74. MarketBeat Community Rating for Dermira (NASDAQ DERM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 337 (Vote Outperform)Underperform Votes: 306 (Vote Underperform)Total Votes: 643MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: How Investors Can Profit from Options Trading
